Biosyent (RX) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue grew 14% year-over-year to $10.18M, with all business segments contributing and record sales achieved in both Q2 and H1 2025.

• EBITDA increased 35% to $2.76M and NIAT rose 28% to $2.02M in Q2 2025, with robust margins and continued profitability.

• Six-month sales reached $21.16M, up 27% year-over-year, with EBITDA up 40% and NIAT up 30%.

• EPS for the trailing 12 months was $0.72, with $0.18 earned in Q2 2025.

• Expanded product portfolio and global reach, including first Tibelia® Global shipments and FeraMAX® leadership.

Financial highlights

• Q2 2025 sales: $10.18M (+14% YoY); H1 2025 sales: $21.16M (+27% YoY).

• Q2 2025 EBITDA: $2.76M (+35% YoY); H1 2025 EBITDA: $5.96M (+40% YoY).

• Q2 2025 NIAT: $2.02M (+28% YoY); H1 2025 NIAT: $4.34M (+30% YoY).

• EBITDA margin: 27% (Q2), 28% (H1); NIAT margin: 20% (Q2), 21% (H1).

• 60th consecutive profitable quarter achieved.

Outlook and guidance

• Strong business momentum expected to continue into Q3 and H2 2025, with further Tibelia® Global shipments planned.

• Continued innovation and expansion of FeraMAX® product line, with new products in development for 2026.

• No expected material impact from tariffs or trade negotiations in 2025 or near-term future.

• Management remains committed to long-term value creation through portfolio diversification and profitable growth.